Giuseppe
Emeritus
J Clin Microbiol. 2009 Mar 25. [Epub ahead of print]
Influenza Antiviral Resistance Testing in New York and Wisconsin, 2006-2008: Methodology and Surveillance Data.
Laplante JM, Marshall SA, Shudt M, Van TT, Reisdorf ES, Mingle LA, Shult PA, St George K. - Wadsworth Center, New York State Department of Health, Albany NY; Wisconsin State Laboratory of Hygiene, 465 Henry Mall Madison WI 53706.
The need for effective influenza antiviral susceptibility surveillance methods has increased, due to the emergence of near-universal adamantane resistance in influenza A/H3N2 viruses during the 2005-06 season, and the appearance of oseltamivir resistance in the influenza A/H1N1 subtype during the 2007-08 season.
The two classes of influenza antivirals, the neuraminidase inhibitors (NAI's) and the adamantanes, are well characterized, as are many mutations that can confer resistance to these drugs.
Adamantane resistance is mainly imparted by a S31N mutation in the matrix gene, while NAI resistance can result from a number of mutations in the neuraminidase gene.
During the 2007-08 season, a neuraminidase mutation (H274Y) conferring resistance to the NAI oseltamivir emerged worldwide, in the A/H1N1 subtype.
Surveillance methodology and data from New York (NY) and Wisconsin (WI) for the 2006-07 and 2007-08 influenza seasons are presented.
We used an existing pyrosequencing method (Bright, R.A., et al. 2005. Lancet 366:1175-1181) and a modified version of this method, for detection of adamantane resistance mutations.
For NAI resistance mutation detection, we used a mutation-specific pyrosequencing technique and developed a neuraminidase gene dideoxy-sequencing method.
Adamantane resistance in A/H3N2 samples was 100% for 2007-08, similar to the 99.8% reported nationwide by CDC.
Adamantane resistance was found in only 1.2% of NY and WI A/H1N1 samples, compared to 10.8% nationwide.
Influenza A/H1N1 H274Y mutants were found in 11.1% of NY samples for 2007-08, a level comparable to the 10.9% reported nationwide by CDC; in contrast, mutants were found in 17.4% of WI samples.
These results indicate the need for regional influenza antiviral surveillance.
PMID: 19321726 [PubMed - as supplied by publisher]
-
------
Influenza Antiviral Resistance Testing in New York and Wisconsin, 2006-2008: Methodology and Surveillance Data.
Laplante JM, Marshall SA, Shudt M, Van TT, Reisdorf ES, Mingle LA, Shult PA, St George K. - Wadsworth Center, New York State Department of Health, Albany NY; Wisconsin State Laboratory of Hygiene, 465 Henry Mall Madison WI 53706.
The need for effective influenza antiviral susceptibility surveillance methods has increased, due to the emergence of near-universal adamantane resistance in influenza A/H3N2 viruses during the 2005-06 season, and the appearance of oseltamivir resistance in the influenza A/H1N1 subtype during the 2007-08 season.
The two classes of influenza antivirals, the neuraminidase inhibitors (NAI's) and the adamantanes, are well characterized, as are many mutations that can confer resistance to these drugs.
Adamantane resistance is mainly imparted by a S31N mutation in the matrix gene, while NAI resistance can result from a number of mutations in the neuraminidase gene.
During the 2007-08 season, a neuraminidase mutation (H274Y) conferring resistance to the NAI oseltamivir emerged worldwide, in the A/H1N1 subtype.
Surveillance methodology and data from New York (NY) and Wisconsin (WI) for the 2006-07 and 2007-08 influenza seasons are presented.
We used an existing pyrosequencing method (Bright, R.A., et al. 2005. Lancet 366:1175-1181) and a modified version of this method, for detection of adamantane resistance mutations.
For NAI resistance mutation detection, we used a mutation-specific pyrosequencing technique and developed a neuraminidase gene dideoxy-sequencing method.
Adamantane resistance in A/H3N2 samples was 100% for 2007-08, similar to the 99.8% reported nationwide by CDC.
Adamantane resistance was found in only 1.2% of NY and WI A/H1N1 samples, compared to 10.8% nationwide.
Influenza A/H1N1 H274Y mutants were found in 11.1% of NY samples for 2007-08, a level comparable to the 10.9% reported nationwide by CDC; in contrast, mutants were found in 17.4% of WI samples.
These results indicate the need for regional influenza antiviral surveillance.
PMID: 19321726 [PubMed - as supplied by publisher]
-
------